Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
30 janv. 2024 17h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr.,...
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
18 janv. 2024 18h10 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive...
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
09 janv. 2024 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of...
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will present at the...
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
21 déc. 2023 08h30 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief...
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
20 déc. 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative...
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
20 nov. 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million...
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
16 nov. 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY and FREMONT, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc., a leader in...
Myriad Genetics to Participate in Stephens Annual Investment Conference
09 nov. 2023 07h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in the...
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
08 nov. 2023 21h20 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced the...